Apricus Biosciences Inc. (APRI) 2009年年度报告「NASDAQ」.pdf

《Apricus Biosciences Inc. (APRI) 2009年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Apricus Biosciences Inc. (APRI) 2009年年度报告「NASDAQ」.pdf（203页珍藏版）》请在三个皮匠报告上搜索。

1、.UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549FORM 10-K(Mark One)xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2009 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF

2、 1934 For the transition period from to Commission file number 0-22245 NEXMED,INC.(Exact Name of Registrant as Specified in Its Charter)Nevada87-0449967(State or Other Jurisdiction of Incorporation orOrganization)(I.R.S.EmployerIdentification No.)6330 Nancy Ridge Drive,Suite 103,San Diego,CA 92121(A

3、ddress of Principal Executive Offices)(Zip Code)(858)222-8041(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of Each ClassName of Exchange on Which RegisteredCommon Stock,par value$.001The NASDAQ Capital Market Securities registered p

4、ursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes _ No

5、 x Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such fi

6、lingrequirements for the past 90 days.Yesx No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data Filerequired to be submitted and posted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during th